Commercial coverage
Does Aetna cover Zepbound?
Zepbound (tirzepatide) for weight loss / obesity — the Aetna prior-authorization rule, source-cited.
Aetna Zepbound PA criteria
Anti-obesity GLP-1 coverage is an OPTIONAL employer benefit many plans exclude entirely.
Where covered: BMI threshold is plan-dependent (BMI >=30, or BMI >=27 with >=1 weight-related comorbidity such as hypertension/T2DM/dyslipidemia on the common 4774-C design; or BMI >=35 with no comorbidity alternative on the stricter 6450-C 'BMI 35' design) plus participation in a >=6-month comprehensive weight-management program (behavior modification, reduced-calorie diet, increased activity).
Pediatric (12-17): Saxenda BMI >=30 adult-equivalent + weight >60 kg; Wegovy BMI >=95th percentile.
Initial approval Wegovy 7mo / Zepbound 8mo / Saxenda 4mo; continuation 12mo requires stable dose >=3mo and >=5% weight loss (Saxenda >=16 weeks + >=4%).
Since 7/1/2025 Wegovy is CVS Caremark's preferred anti-obesity GLP-1 and Zepbound was dropped from the standard preferred commercial formulary (does not affect diabetes form Mounjaro).
Source: Aetna Pharmacy Clinical Policy Bulletins 4774-C (Wegovy) / 6450-C (Weight Loss BMI 35) / 5694-D (Antidiabetic GLP-1) / 5468-C (Mounjaro). View cited GLP-1 policy reference →
Note: tirzepatide is also sold as Mounjaro for type 2 diabetes, which Aetna evaluates under a separate type 2 diabetes policy (not this one) — see does Aetna cover Mounjaro?. Coverage follows the brand's FDA indication, not the molecule.
Frequently asked
- Does Aetna cover Zepbound for weight loss / obesity?
- Varies by plan — PA required where covered. Anti-obesity GLP-1 coverage is an OPTIONAL employer benefit many plans exclude entirely. See the full source-cited criteria above. Per Aetna Pharmacy Clinical Policy Bulletins 4774-C (Wegovy) / 6450-C (Weight Loss BMI 35) / 5694-D (Antidiabetic GLP-1) / 5468-C (Mounjaro), as of 2026 (4774-C updated 05/01/2024; 6450-C eff. 08/15/2024; 5694-D updated 10/15/2023; 5468-C updated 10/27/2024; CVS Caremark formulary change eff. 07/01/2025) — confirm the member's current plan policy.
d3rx does not hold plan-specific pharmacy formularies or PBM prior-auth grids, so it cannot confirm a particular plan's GLP-1 coverage, tier, or PA criteria. The guidance below is the general, source-cited rule; confirm the specific plan's pharmacy formulary / PA policy for a binding answer.
Check Zepbound for another payer — or draft the PA
Run Zepbound + any payer in the GLP-1 PA lookup, or have Ask D3 draft a Aetna-ready prior-authorization request with the right criteria and codes — free, no signup.